ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 315 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $299,000 | -6.3% | 9,050 | 0.0% | 0.08% | -8.9% |
| Q2 2022 | $319,000 | -23.3% | 9,050 | 0.0% | 0.09% | -2.2% |
| Q1 2022 | $416,000 | -30.7% | 9,050 | 0.0% | 0.09% | -30.8% |
| Q4 2021 | $600,000 | +6.2% | 9,050 | 0.0% | 0.13% | -8.3% |
| Q3 2021 | $565,000 | -24.7% | 9,050 | 0.0% | 0.14% | -20.8% |
| Q2 2021 | $750,000 | +25.0% | 9,050 | 0.0% | 0.18% | +19.6% |
| Q1 2021 | $600,000 | -13.5% | 9,050 | 0.0% | 0.15% | -18.2% |
| Q4 2020 | $694,000 | +77.9% | 9,050 | 0.0% | 0.19% | +49.6% |
| Q3 2020 | $390,000 | -0.3% | 9,050 | 0.0% | 0.12% | -11.3% |
| Q2 2020 | $391,000 | +41.7% | 9,050 | -5.6% | 0.14% | +20.5% |
| Q1 2020 | $276,000 | -51.1% | 9,585 | +7.9% | 0.12% | -44.3% |
| Q4 2019 | $564,000 | +125.6% | 8,885 | 0.0% | 0.21% | +105.9% |
| Q3 2019 | $250,000 | +6.4% | 8,885 | 0.0% | 0.10% | +5.2% |
| Q2 2019 | $235,000 | – | 8,885 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,264 | $54,392,000 | 33.22% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $216,228,000 | 28.00% |
| L1 Capital Pty Ltd | 296,024 | $19,629,000 | 4.93% |
| Aquilo Capital Management, LLC | 407,926 | $27,050,000 | 4.89% |
| Evolutionary Tree Capital Management, LLC | 72,948 | $4,837,000 | 2.86% |
| ACUTA CAPITAL PARTNERS, LLC | 108,000 | $7,161,000 | 2.58% |
| First Light Asset Management, LLC | 536,836 | $35,598,000 | 2.36% |
| Parkman Healthcare Partners LLC | 70,089 | $4,648,000 | 1.08% |
| Hood River Capital Management LLC | 357,082 | $23,678,000 | 0.76% |
| Vanguard Capital Wealth Advisors | 11,099 | $703,565,000 | 0.60% |